OptiMega-3® Q10

OptiMega-3® Q10

Pharmaceutical Grade

60 ( SKU: 9322, NPN: 80029633 )

Benefits

  • Provides 600 mg EPA, 300 mg DHA, and 100 mg CoQ10 per softgel
  • Optimal 2:1 ratio EPA to DHA
  • This pharmaceutical grade omega-3 blend fish oil has achieved the highest USP standard, verified for quality and consistency
  • Stringent quality control standards ensure that this highly purified fish oil concentrate is free of lipid peroxides and environmental pollutants, including heavy metals, pesticides, dioxins, PCBs, and other harmful compounds
  • Highly bioavailable softgel

Feature Summary

This high potency combination of CoQ10 and the omega-3 fatty acids EPA/DHA provides cardiovascular and cognitive benefit through multiple distinct and overlapping pathways. Both CoQ10 and DHA/EPA have been shown to improve endothelial function, with clinically significant hypotensive and anti-atherogenic effects.1,2,3 CoQ10 has an instrumental role in oxidative phosphorylation and mitochondrial bioenergetics, critical to neuronal health and preventing the mitochondrial dysfunction that underlies numerous chronic diseases, including neurodegenerative disease.4 Additionally, recent data highlights CoQ10’s emerging role in reducing inflammation and insulin resistance, which are potent contributors to impaired cognitive function.5,6,7

OptiMega-3 Q10 also provides high dose pharmaceutical grade EPA/DHA, shown to reduce many cardiovascular risk factors and improve vascular function, with controlled clinical trials demonstrating a reduced rate of cardiovascular events, cardiac death and coronary events, particularly in persons at high risk.8-12 Omega-3 fatty acids have been associated with reduced all-cause mortality, sudden death, myocardial infarction, as well as stroke.13,14,15 EPA/DHA support cognitive function through multiple mechanisms, as both are indispensable to neuronal membranes, with lower levels found to be not only a marker for neurological disease but also a risk factor for cognitive impairment.16,17

Medicinal Ingredients

Serving Size: 1 EnteripureTM Softgel
Servings per Container: 60

Each Enteripure Softgel Contains:
Fish Oil Concentrate (Molecularly Distilled, Ultra Purified)
(Anchovy, Sardine and/or Mackerel)......................1407 mg
Omega-3 Fatty Acids ...............................................900 mg
Eicosapentaenoic Acid (EPA) ................................600 mg
Docosahexaenoic Acid (DHA) ...............................300 mg
Coenzyme Q10 (Microorganism) ...............................100 mg

Non-Medicinal Ingredients

Enteripure softgel (gelatin, glycerin, purified water, pectin), natural vitamin E.

Allergens:

Contains no artificial colours, preservatives, or sweeteners; no dairy, sugar, wheat, gluten, yeast, corn, egg, shellfish, salt, tree nuts, or GMOs. Sealed for your protection. Do not use if seal is broken. Store in airtight container, protected from light. For freshness, store in a cool, dry place.

Contraindications

Consult a health care practitioner prior to use if you are pregnant or breastfeeding, or if you are taking blood thinners or blood pressure medication. Keep out of reach of children.

Drug Interactions

Because fish oil has an antithrombotic effect, caution is advised for those on anticlotting, antiplatelet or anticoagulant medications, or those at high risk of bleeding.18 At doses greater than 3 g per day, hyperglycemia has been observed in diabetics and those with hypertriglyceridemia, close monitoring of patients on antidiabetic medication is recommended. Benefits have been shown when fish oil is taken with statins, SSRIs, anticonvulsant and cytotoxic medications.19,20 CoQ10 resembles vitamin K structurally, and there is a potential interaction possible for those taking the anticoagulant Coumadin. Close monitoring of the INR is recommended with CoQ10 introduction in these patients.

  1. Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 2014 Jul;27(7):885-96. doi: 10.1093/ajh/hpu024.
  2. Gao L, Mao Q, Cao J, et al. Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012 Apr;221(2):311-6. doi: 10.1016/j.atherosclerosis.2011.
  3. Rosenfeldt FL, Haas SJ, Krum H, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007 Apr;21(4):297-306.
  4. Du H, Yan SS. Mitochondrial medicine for neurodegenerative diseases. Int J Biochem Cell Biol. 2010 May;42(5):560-72. doi: 10.1016/j.biocel.2010.01.004.
  5. Farsi F, Mohammadshahi M, Alavinejad P, et al. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double- Blind, Placebo-Controlled, Randomized Clinical Trial. J Am Coll Nutr. 2015 Jul 9:1-8. [Epub ahead of print]
  6. de la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol. 2014 Apr 15;88(4):548-59.
  7. Yates KF, Sweat V, Yau PL, Turchiano MM, et al. Impact of metabolic syndrome on cognition and brain: a selected review of the literature. Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2060-7.
  8. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, et al. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr. 2012 Jun;107 Suppl 2:S201-13. doi: 10.1017/S0007114512001596.
  9. Pischon T, Hankinson SE, Hotamisligil GS, et al. Habitual dietary intake of omega-3 and omega-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003 Jul 15;108(2):155-60.
  10. Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr. 2012;3:1-7.
  11. Wang C, Harris WS, Chung M, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006 Jul;84(1):5-17.
  12. Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008 Sep;200(1):135-40.
  13. Pottala JV, Garg S, Cohen BE, et al. Blood eicosapentaenoic and docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: the Heart and Soul study. Circ Cardiovasc Qual Outcomes. 2010 Jul;3(4):406-12.
  14. Casula M, Soranna D, Catapano AL, et al. Atheroscler Suppl. 2013 Aug;14(2):243-51.
  15. Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008 Jul;39(7):2052-8.
  16. Lin PY, Chiu CC, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in dementia. J Clin Psychiatry. 2012 Sep;73(9):1245-54.
  17. Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015 Apr 21;7:52.
  18. Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol. 2007 Mar 19;99(6A):44C-46C.
  19. Toyama K, Nishioka T, Isshiki A, et al. Eicosapentaenoic Acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease. Cardiovasc Drugs Ther. 2014 Feb;28(1):53-9.
  20. Mischoulon D, Freeman MP. Omega-3 fatty acids in psychiatry. Psychiatr Clin North Am. 2013 Mar;36(1):15-23.